Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Economic burden and healthcare resource utilization
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Primary central nervous system lymphoma

Economic burden and healthcare resource utilization

1 evidence topic · 1 source

PCNSL economic burden: Taiwan

“mean direct healthcare costs exceeding 1 million TWD (35,000 USD) concentrated within the first year following diagnosis.” (opens the source at this quote in a new tab)